Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8238 results

  1. OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]

    Awaiting development Reference number: GID-TA11905 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Delgocitinib for Chronic Hand Eczema [ID6688]

    Awaiting development Reference number: GID-TA11777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development

  4. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

    NICE guideline
    In development

  5. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]

    In development Reference number: GID-TA11478 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  8. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  10. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  11. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 January 2026.

    Technology appraisal guidance
    In consultation

  12. Perioperative care in adults: quality standard consultation

    We are listening to your views on this Quality standard. Comments close 6 February 2026.

    Quality standard
    In consultation

  13. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  15. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development